Truist analyst Michael Roxland lowered the firm’s price target on Sealed Air to $38 from $43 and keeps a Hold rating on the shares. The analyst is citing various headwinds in both Food and Protective that inhibit the company’s EBITDA and volume growth, the analyst tells investors in a research note, also stating that Sealed Air’s Cryovac business is facing increasing competitive threats. Truist adds that Sealed Air’s leverage remains elevated as it is limited in its ability to reduce debt in 2023 given its $175M IRS tax settlement payment.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on SEE:
- Early notable gainers among liquid option names on September 25th
- Citi Sealed Air to Buy, sees end of negative earnings revisions
- Sealed Air upgraded to Buy from Neutral at Citi
- General Motors upgraded, Oracle downgraded: Wall Street’s top analyst calls
- Sealed Air upgraded to Outperform from Neutral at Credit Suisse